STAT3 and cancer: The IL-6/STAT3 signaling pathway may play an essential role in the TIME; IL-6-mediated STAT3 activation in the TME inhibits the functional maturation of DCs, thus activating effector T cells and blocking the emergence of anti-tumor immunity in cancers (103).